The effect of Enoxaparin and Aspirin for the prevention of thrombosis after open splenectomy

Clinical trial of evaluation of effect of Enoxaparin and Aspirin in portal, splenic, and superior mesentrics vein thrombosis after open splenectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016042527600N1

Enrollment

126

Registered

2016-06-12

Start date

2015-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

open splenectomy. Disease of spleen, unspecified

Interventions

Intervention 1: Intervention Group: 40mg subcutaneous daily Enoxaparin for 7 days and then 100mg oral daily A.S.A tablets for 30 days after surgery. Intervention 2: Control Group: without administrati

Prevention

Intervention Group: 40mg subcutaneous daily Enoxaparin for 7 days and then 100mg oral daily A.S.A tablets for 30 days after surgery

Control Group: without administrating of drug

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients who underwent open Splenectomy for any reason from 21 may 2015 to 22 may 2016 in Golestan Hospital, Ahvaz, Iran Exclusion Criteria: Uncooperative patients to ultrasound follow up; Patients' death; A history of venous thrombosis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Thrombosis of Splenic, Portal, and Superior Mesentric vein. Timepoint: 5 weeks after initiate of intervention. Method of measurement: color doppler ultrasonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMosayeb Rafiee Pour

Ahvaz Jundishapur University of Medical Sience

info@ajums.ac.ir; rafieepour.m@ajums.ac.ir+98 61 3335 3179

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026